{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Treatment+of+Hepatitis+C&page=18", "query": { "condition": "Treatment of Hepatitis C", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 448, "total_pages": 45, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Treatment+of+Hepatitis+C&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Treatment+of+Hepatitis+C&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T08:47:10.242Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01492504", "title": "Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1850, "start_date": "2012-02-07", "completion_date": "2018-03-19", "has_results": false, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-10-15T08:47:10.242Z", "location_count": 50, "location_summary": "Montgomery, Alabama • Beverly Hills, California • Coronado, California + 37 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01492504" }, { "nct_id": "NCT02304159", "title": "Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C", "Cirrhosis" ], "interventions": [ { "name": "daclatasvir", "type": "DRUG" }, { "name": "Sofosbuvir, Sovaldi", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tarek I. Hassanein, M.D., FACP, FAG, AGAF", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 39, "start_date": "2015-01", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2019-04-24", "last_synced_at": "2026-10-15T08:47:10.242Z", "location_count": 1, "location_summary": "Coronado, California", "locations": [ { "city": "Coronado", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02304159" }, { "nct_id": "NCT01314261", "title": "Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C", "Hepatitis C Virus (HCV) Infection" ], "interventions": [ { "name": "ABT-267", "type": "DRUG" }, { "name": "Pegylated interferon (pegIFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "Placebo for ABT-267", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2011-03", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-10-15T08:47:10.242Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01314261" }, { "nct_id": "NCT00078403", "title": "Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C", "Liver Disease" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2004-07", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2021-11-08", "last_synced_at": "2026-10-15T08:47:10.242Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078403" }, { "nct_id": "NCT01909804", "title": "Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "VEL", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2013-06", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-11-15", "last_synced_at": "2026-10-15T08:47:10.242Z", "location_count": 40, "location_summary": "Long Beach, California • Los Angeles, California • Pasadena, California + 37 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01909804" }, { "nct_id": "NCT01165359", "title": "Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "ITX 5061", "type": "DRUG" }, { "name": "Placebo ITX 5061", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2010-09", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-15T08:47:10.242Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01165359" }, { "nct_id": "NCT01225380", "title": "A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Infection" ], "interventions": [ { "name": "GS-9190", "type": "DRUG" }, { "name": "GS-9256", "type": "DRUG" }, { "name": "Pegasys®", "type": "BIOLOGICAL" }, { "name": "Copegus®", "type": "DRUG" }, { "name": "GS-9190 placebo", "type": "DRUG" }, { "name": "GS-9256 placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 324, "start_date": "2010-10", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-01-28", "last_synced_at": "2026-10-15T08:47:10.242Z", "location_count": 36, "location_summary": "Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01225380" }, { "nct_id": "NCT01434498", "title": "GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Genotype 1a or 1b HCV Infection" ], "interventions": [ { "name": "GS-5885 tablet", "type": "DRUG" }, { "name": "GS-9451 tablet", "type": "DRUG" }, { "name": "tegobuvir capsule", "type": "DRUG" }, { "name": "ribavirin tablet", "type": "DRUG" }, { "name": "placebo matching ribavirin tablet", "type": "DRUG" }, { "name": "placebo matching tegobuvir capsule", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 163, "start_date": "2011-09", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2013-12-20", "last_synced_at": "2026-10-15T08:47:10.242Z", "location_count": 36, "location_summary": "Beverly Hills, California • Coronado, California • La Jolla, California + 28 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01434498" }, { "nct_id": "NCT00381433", "title": "Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Encephalitis" ], "interventions": [ { "name": "AVI-4065 Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "MALE", "summary": "18 Years to 64 Years · Male only" }, "enrollment_count": 12, "start_date": "2006-09", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2009-07-08", "last_synced_at": "2026-10-15T08:47:10.242Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381433" }, { "nct_id": "NCT00516321", "title": "Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "eltrombopag", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 687, "start_date": "2007-10", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2013-11-05", "last_synced_at": "2026-10-15T08:47:10.242Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00516321" } ] }